Trial Profile
A Phase II single centre, open-label study investigating the pharmacokinetics, pharmacodynamics, efficacy and safety of a loading dose regimen of a new GnRH antagonist, Teverelix, long-acting formulation administered subcutaneously as two doses of 120 mg (given as 2 injections of 60 mg on Day 1 and repeated on Day 2) in patients with advanced prostate cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 May 2011
Price :
$35
*
At a glance
- Drugs Teverelix (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Ardana plc
- 26 May 2011 New trial record